---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-266836"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:18:19.121545+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines Q3 net loss $305.2M; advancing daraxonrasib pivotal trials

## Summary
- Net loss $305.2M vs $156.3M YoY; R&D expense $262.5M (+73%), G&A $52.8M (+120%).
- Cash, equivalents & securities $1.93B; full-year GAAP net loss guidance reaffirmed at $1.03B-$1.09B.
- RASolute 302 (PDAC) enrollment winding down; data readout on track for 2026.
- RASolute 304 (adjuvant PDAC) initiated; RASolute 303 (1L metastatic PDAC) expected to start this year.
- New CDO Alan Sandler, U.S. GM Alicia Gardner, Europe GM Gerwin Winter appointed.

## SEC filing metadata
- accession: 0001193125-25-266836
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312525266836/0001193125-25-266836-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312525266836/rvmd-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-266836
- JSON: https://secwatch.observer/filing/0001193125-25-266836.json
- Plain text: https://secwatch.observer/filing/0001193125-25-266836.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.